Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. - Test2 - elhamkhani - TriplyDB

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

http://www.wikidata.org/entity/Q34758422

about

Hormone therapy for preventing cardiovascular disease in post-menopausal women Hormone therapy for preventing cardiovascular disease in post-menopausal women Long term hormone therapy for perimenopausal and postmenopausal women Lung cancer: epidemiology, etiology, and prevention Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk Nonadherence to treatment protocol in published randomised controlled trials: a review Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective Sex differences in stroke: the contribution of coagulation Long-term hormone therapy for perimenopausal and postmenopausal women.New evidence for cardiac benefit of postmenopausal hormone therapy.Advances in the treatment of menopausal symptoms.The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk.Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk Recent trends in breast cancer incidence in US white women by county-level urban/rural and poverty status.Observations following discontinuation of long-term denosumab therapy.Mammographic screening and risk factors for breast cancer Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.Factors associated with successful discontinuation of hormone therapy.Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study Primary and secondary prevention of colorectal cancer Exposure to statins and risk of common cancers: a series of nested case-control studies.Intent-to-Treat vs. Non-Intent-to-Treat Analyses under Treatment Non-Adherence in Mental Health Randomized Trials.Mammographic breast density and tolerance for short-term postmenopausal hormone therapy suspension The 2012 hormone therapy position statement of: The North American Menopause Society.Chains of evidence, mosaics of data: does estrogen 'cause' breast cancer? How would we know?Effects of adenosine monophosphate used in combination with L-arginine on female rabbit corpus cavernosum tissue Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke.Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative.Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD Stratified pathway analysis to identify gene sets associated with oral contraceptive use and breast cancer.Hyaluronic acid prevents immunosuppressive drug-induced ovarian damage via up-regulating PGRMC1 expression.Breast cancer after use of estrogen plus progestin in postmenopausal women.A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age.

P2860

Q24187326-D2A0B96A-308C-4070-89C6-E0235A3DE129 Q24197712-FA8F7B15-43F3-4CE8-A183-946641D683F8 Q24201974-F560C0C9-F477-45FA-87BC-93E9045469B4 Q24630167-5252A883-84B9-4776-AF41-D67C6638F521 Q24658109-8F2B721E-2ED0-4675-8FBB-5F6F97E601C5 Q26800279-B232083F-F7A3-4560-8F20-082AD6E959BE Q26821782-8A325461-53A9-49D6-B783-5DD29C775846 Q26825321-59D8AB30-504E-4AE7-8FE3-64BC1339635E Q26864207-C24D5B65-A352-44F8-8222-6965E8858116 Q27022768-D841F230-2676-4CAB-BEED-F09FF9B72281 Q30238978-110F8EDE-4E65-46C0-9447-A19FB7F01F6F Q30396979-BB6465C3-D1BB-43FE-8F90-9A674AE00028 Q30448720-8B17F66C-2BAB-47AF-93DB-161649FE89B1 Q30485457-9AD66790-A2B7-41A2-BEDE-A5C1622670E3 Q30491822-2284611A-EDD9-4A88-934D-A83181784260 Q33475114-29847FA2-0C58-4DE6-8F59-67476CB4F256 Q33563846-CC297378-8596-4EC6-84A6-DC2232303741 Q33566626-2598067D-4CF4-46EC-916D-CA54D189A2F6 Q33569159-0DF3D7C0-D952-4D2B-85E6-B21B5B404DB1 Q33571609-6192E060-756D-45F8-A31D-0C6DAE8131C2 Q33711732-2A0553BF-2B7E-48BE-857E-DF0EB3D47861 Q33770389-2A90704E-532F-4B7A-87E3-5EF0E2FAFF04 Q33976246-2F341B99-8CA1-4360-9649-D0314C578A6A Q34028899-5E53A4F3-8E28-4D7A-A97A-2942D8E37478 Q34066072-47A4121C-DE30-40EE-BD35-93C67FCD8C91 Q34137122-7F426CB7-1C69-436F-81DE-6719F83EFFC2 Q34161400-DB3F1AC0-D886-408A-8A53-3291951C824F Q34285969-B03DD4E9-C77B-48E7-A8C9-7906E7465F9F Q34286586-B20A7169-9AAB-400F-9A4C-6642B92B0221 Q34315478-5C0A4260-8EEC-416F-ACB0-461203EE4D72 Q34321877-7BC0BE90-8AFB-4F6A-8C6C-9F84074A80C7 Q34370566-156CE1EE-A581-42ED-8B0A-A6A0F2B118F3 Q34420014-8A3B25AD-21EF-4AD7-9B0C-19CDDCD34B4B Q34449454-A2902008-2A24-411D-884F-B2A5F388F60B Q34475143-C0F31C3A-18BF-41A2-A496-5224948B165E Q34575982-008D8DCF-1099-40D6-A1F0-194543D37608 Q34680457-C902353A-486D-482D-BBAB-6F164EB7BC85 Q34830224-223F69BC-8F1C-43F4-9F83-4FE064EC905B Q34938322-64350391-2773-4E10-AA7E-DF615595AA27 Q35035445-8B50DD64-672E-4B33-90F8-CED841F7727E

P2860

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

http://www.wikidata.org/entity/Q34758422

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@ast

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@en

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@nl

type

label

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@ast

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@en

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@nl

prefLabel

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@ast

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@en

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@nl

P1433

Q34758422-3B37D6A4-D126-4860-86F6-E473B17F61FC

P1476

Q34758422-C89888D4-1B40-471E-AD26-5F9C54AC85EE

P2093

Q34758422-02E3C96D-231F-4D70-9E0A-7A334B8E7940

Q34758422-05DD39FB-F37B-43A6-847A-E9F4F97AA29B

Q34758422-27F073C4-6997-4F1A-8B20-ED85DBDDC819

Q34758422-290B4D8E-F731-422C-9AB2-719F216DF0DD

Q34758422-3250D178-4A6A-47A4-9EC9-DF84B84A6F20

Q34758422-3604D6AD-A0DF-4166-A2FC-EA81013099A7

Q34758422-6BF6109C-353B-4B73-8578-4971E3F1E847

Q34758422-90F14FEA-7A36-4EAB-B404-9B75E9752456

Q34758422-9F57DFA9-6A83-4A8F-8EFF-A869AE15C338

Q34758422-BFA9B93A-8E7D-43F2-A4D2-47C06384CFC6

P304

Q34758422-0D00B6AA-9601-4294-8EE7-3993CE7B4226

P31

Q34758422-1C706E65-885D-44DC-9510-BFDDE29B3D0F

P356

Q34758422-111CB3DD-C366-4A3B-9E72-FBECC9EDF98F

P407

Q34758422-C1F7F9E2-2EB6-4013-A3AB-03C37EDA86F1

P433

Q34758422-DE438B43-0B76-4CF3-B954-17A1E93501B0

P478

Q34758422-1E5A7315-9462-433C-97E5-ECD250D1580D

P50

Q34758422-8A3C1BAB-0072-4D4B-B6EB-313BC7308630

P577

Q34758422-96BC1E11-6111-4FBF-999F-68F4E20EC75B

P5875

Q34758422-548CE3C9-E582-4D03-9229-43E43CF6FBFB

P698

Q34758422-DE2905EC-ADCB-45E4-9D89-8A1820EE09B1

P356

JAMA.299.9.1036

P1433

Journal of the American Medical Association

P1476

Health risks and benefits 3 ye ...... t with estrogen and progestin.

@en

P2093

Aaron Aragaki

http://www.w3.org/2001/XMLSchema#string

Andrea LaCroix

http://www.w3.org/2001/XMLSchema#string

Garnet L Anderson

http://www.w3.org/2001/XMLSchema#string

Jacques Rossouw

http://www.w3.org/2001/XMLSchema#string

JoAnn E Manson

http://www.w3.org/2001/XMLSchema#string

Marcia L Stefanick

http://www.w3.org/2001/XMLSchema#string

Margery Gass

http://www.w3.org/2001/XMLSchema#string

Robert Brzyski

http://www.w3.org/2001/XMLSchema#string

Robert Wallace

http://www.w3.org/2001/XMLSchema#string

Ross L Prentice

http://www.w3.org/2001/XMLSchema#string

P304

1036-1045

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.299.9.1036

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

299

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5533661

http://www.w3.org/2001/XMLSchema#string

P698

18319414

http://www.w3.org/2001/XMLSchema#string